IL-15 Superagonist + Vaccine for Prostate Cancer

This trial explores whether a new drug, N-803 (an IL-15 superagonist), alone or combined with a vaccine named ETBX-071, can lower PSA levels in men with biochemically recurrent prostate cancer. Researchers focus on individuals who have previously undergone targeted radiation treatment (SBRT) but still experience rising PSA levels, indicating potential cancer recurrence. Ideal candidates for this trial include those who have had prostate cancer surgery or radiation, have rising PSA levels, and have received SBRT in the past. Participants will receive injections of the study drug(s) and undergo close monitoring over several months. As a Phase 2 trial, the research measures the treatment's effectiveness in an initial, smaller group of people.

The trial requires that you stop taking certain medications, such as systemic corticosteroids and medications for urinary symptoms like 5-alpha reductase inhibitors, at least 28 days before starting the study treatment. If you're on any other medications, it's best to discuss them with the trial team to see if they might affect your participation.

Previous studies have shown that N-803, a medicine that boosts the immune system, is safe and well-tolerated. Research indicates that it helps immune cells fight cancer without causing serious side effects. In one study, only 1% of patients experienced serious side effects related to the treatment, and no deaths were linked to it. Some mild side effects included discomfort during urination in about 22% of patients.

Less information is available about the combination of N-803 with the ETBX-071 vaccine. The ETBX-071 vaccine is designed to help the immune system better target prostate cancer cells. While specific safety data on this combination is limited, it is being tested in a mid-stage clinical trial, which usually means some safety information is already available from earlier studies.

Unlike the standard treatments for prostate cancer, which typically include hormone therapy, chemotherapy, and radiation, the combination of N-803 and the ETBX-071 vaccine is breaking new ground. N-803 acts as an IL-15 superagonist, a novel mechanism that boosts the immune system’s natural ability to fight cancer by activating and proliferating immune cells. The addition of the ETBX-071 vaccine is intended to specifically target prostate cancer cells, potentially enhancing the body’s immune response against the tumor. Researchers are excited about these treatments because they offer a dual approach that both strengthens the immune system and directs it specifically against prostate cancer, promising a more targeted and potentially effective treatment.

Studies have shown that N-803, a drug that boosts the immune system, yields promising results in cancer treatment. For some patients with non-muscle-invasive bladder cancer, it achieved a 71% complete response rate when combined with another therapy. Research indicates that N-803 has also been linked to decreases in PSA levels, markers for prostate cancer, in patients with this condition. In this trial, one group of participants will receive N-803 alone, while another group will receive a combination of N-803 with the ETBX-071 vaccine. Earlier trials have shown this combination may lower PSA levels and improve survival rates, suggesting it could strengthen the immune response against prostate cancer.⁴⁶⁷⁸⁹